Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ADMA Biologics, Inc. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired ADMA securities between August 9, 2024 and March 25, 2026. The complaint claims the company made false or misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors have until August 10, 2026 to seek lead plaintiff appointment. The law firm is handling the case on a contingency fee basis.
ADMA Biologics IncClass action lawsuit alleging securities fraud and false statements.